

Supplemental Table S1: Clinical and biochemical features of the control group included in the association analysis of the rs72613567 variant and NAFLD (fatty liver) as disease trait

Variables	Control subjects (no-NAFLD) that matched patients with NAFLD-MetS	Control subjects (no-NAFLD) that matched morbidly obese patients with NAFLD
Number of subjects	147	33
Female, %	59	70
Age, years	45±19	40±12
BMI, kg/m²	25±4	54±11
Fasting plasma glucose, mg/dL	84±15	98±17
Fasting plasma insulin, µU/ml	6.8±4.7	12±6
HOMA-IR index	1.44±1.05	2.88±1.7
Hb1C	5.3±1.2	6.1±1.2
Total cholesterol, mg/dL	204±41	181±38
HDL-cholesterol, mg/dL	56±16	40±8.5
LDL-cholesterol, mg/dL	124±38	118±31
Triglycerides, mg/dL	120±78	136±57
Uric acid, mg/dL	3.4±1.4	5.7±1.8
ALT, U/L	22±4	23±9
AST, U/L	18±3	21±11

BMI: body mass index; HOMA: homeostatic model assessment; HbA1c: glycated haemoglobin; ALT and AST: Serum alanine and aspartate aminotransferase. Results are expressed as mean±SD.